Kivu Bioscience closes series A financing to advance ADC pipeline into clinic

Oct. 29, 2024

Kivu Bioscience has closed a $92 million series A financing to advance its topoisomerase I inhibitor-based antibody-drug conjugate (ADC) pipeline into the clinic.

BioWorld Science Financings Cancer Antibody-drug conjugate Immuno-oncology Series A

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 31, 2025

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal

BioWorld Science

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...

Corcept looks to NDA following strong phase III ovarian cancer data

BioWorld

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...

Otsuka submits first BLA to FDA for sibeprenlimab in IgAN

BioWorld

Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The...